Skip to main content
S&P 5007,688.62+1.58%DOW53,356.12+3.03%NASDAQ25,736.51+1.44%BTC$80,787.00+5.07%ETH$2,431.65+7.47%GOLD$4,134.30+1.51%OIL$87.17-1.08%
Smart Investors Daily
SID Premium
CSPC Pharmaceutical Group Limited logo

OTC · CSPCY

CSPC Pharmaceutical Group Limited

Healthcare · Drug Manufacturers - General

$4.15

Up+$0.09 (+2.09%)

Updated Nov 5, 2026, 6:39 AM

SID Score

5.9/10

Composite research score

Smart Money

46/100

Neutral

Market cap
11.3B
P/E ratio
18.57
Dividend yield
2.96%
52-week range
— – —
Volume
1.26K
Avg. volume
37.17K

Price performance · CSPCY

CSPCY price history

1M range · 0 trading sessions · Daily adjusted prices

CSPCY does not have enough price history for the selected period.

Data unavailable

The requested market data was not found.

Latest CSPCY news

The latest Smart Investors Daily articles mentioning CSPCY.

Stock researchCompany · Overview

CSPCY research

Overview

Company profile and research snapshot.

Company profile

CSPC PHARMS GRP U/ADR

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 28, 2026

CSPC Pharmaceutical Group (SEHK:1093) Stock May Be 44% Undervalued On RSV Trial Start

CSPC Pharmaceutical Group has delivered a 31.5% share price gain over the past three years, while the news flow around its experimental cancer and RSV treatments has picked up. This puts the spotlight on a simple question for you as an investor: Is the current Hong Kong share price adequately supported by the cash flows that CSPC Pharmaceutical Group can generate over time? The 31.5% return over three years puts real weight on whether the recent share performance is aligned with what the...

Yahoo · Oct 15, 2026

CSPC Pharmaceutical Group (SEHK:1093) Reports Encouraging SYS6002 Data, Is The Valuation Gap Still Open?

CSPC Pharmaceutical Group (SEHK:1093) has drawn fresh attention after presenting Phase I data for its Nectin-4 targeted antibody drug conjugate SYS6002 in advanced cervical cancer at IGCS2026, covering safety, tolerability and early response metrics. CSPC Pharmaceutical Group shares now trade at HK$8.865, with a 90 day share price return of 9.44% and a year to date share price gain of 4.54%. The 1 year total shareholder return is slightly down 0.73% despite a strong 76.74% total shareholder...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By